Browsing NTNU Open by Author "Våtsveen, Thea Kristin"

Now showing items 1-8 of 8

    • Artesunate shows potent anti-tumor activity in B-cell lymphoma 

      Våtsveen, Thea Kristin; Myhre, Marit Renee; Steen, Chloe Beate; Wälchli, Sébastien; Lingjærde, Ole Christian; Bai, Baoyan; Dillard, Pierre; Theodossiou, Theodossis; Holien, Toril; Sundan, Anders; Inderberg, Else Marit; Smeland, Erlend B; Myklebust, June; Oksvold, Morten Pedersen (Journal article; Peer reviewed, 2018)
      Background Although chemo-immunotherapy has led to an improved overall survival for most B-cell lymphoma types, relapsed and refractory disease remains a challenge. The malaria drug artesunate has previously been identified ...

    • Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin 

      Olsen, Oddrun Elise; Wader, Karin Fahl; Misund, Kristine; Våtsveen, Thea Kristin; Rø, Torstein Baade; Mylin, Anne K.; Turesson, I; Størdal, Berit Fladvad; Moen, Siv Helen; Standal, Therese; Waage, Anders; Sundan, Anders; Holien, Toril (Journal article; Peer reviewed, 2014)
      Multiple myeloma is a malignancy of plasma cells predominantly located in the bone marrow. A number of bone morphogenetic proteins (BMPs) induce apoptosis in myeloma cells in vitro, and with this study we add BMP-9 to the ...

    • Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro 

      Våtsveen, Thea Kristin; Sponaas, Anne Marit; Tian, Erming; Zhang, Qing; Misund, Kristine; Sundan, Anders; Børset, Magne; Waage, Anders; Brede, Gaute (Journal article; Peer reviewed, 2016)
      Background: Multiple myeloma is an incurable complex disease characterized by clonal proliferation of malignant plasma cells in a hypoxic bone marrow environment. Hypoxia-dependent erythropoietin (EPO)-receptor (EPOR) ...

    • Genetic Aberrationsin Myeloma Cells 

      Våtsveen, Thea Kristin (Doktoravhandlinger ved NTNU, 1503-8181; 2009:83, Doctoral thesis, 2009)
      Genetiske avvik i myelomceller Myelomatose (beinmargskreft) er kreft i plasmacellene i beinmargen. Det er den nest vanligste hematologiske kreftformen og rammer ca 300 personer i Norge hvert år. Kun 15% av pasientene er ...

    • Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients 

      Rampa, Christoph Samuel; Tian, Erming; Våtsveen, Thea Kristin; Buene, Glenn; Slørdahl, Tobias Schmidt; Børset, Magne; Waage, Anders; Sundan, Anders (Journal article; Peer reviewed, 2014)
      Background Hepatocyte growth factor (HGF) is a pleiotropic cytokine which can lead to cancer cell proliferation, migration and metastasis. In multiple myeloma (MM) patients it is an abundant component of the bone marrow. ...

    • Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration 

      Vandsemb, Esten Nymoen; Bertilsson, Helena; Abdollahi, Pegah; Størkersen, Øystein; Våtsveen, Thea Kristin; Rye, Morten Beck; Rø, Torstein Baade; Børset, Magne; Slørdahl, Tobias Schmidt (Journal article; Peer reviewed, 2016)
      Background: PRL-3 is a phosphatase implicated in oncogenesis in multiple cancers. In some cancers, notably carcinomas, PRL-3 is also associated with inferior prognosis and increased metastatic potential. In this study we ...

    • Targeting Proliferating Cell Nuclear Antigen and Its Protein Interactions Induces Apoptosis in Multiple Myeloma Cells 

      Müller, Rebekka; Misund, Kristine; Holien, Toril; Bachke, Siri; Gilljam, Karin Margaretha; Våtsveen, Thea Kristin; Rø, Torstein Baade; Bellacchio, E.; Sundan, Anders; Otterlei, Marit (Journal article; Peer reviewed, 2013)
      Multiple myeloma is a hematological cancer that is considered incurable despite advances in treatment strategy during the last decade. Therapies targeting single pathways are unlikely to succeed due to the heterogeneous ...

    • The role of CD1d in survival and growth of hyperdiploid multiple myeloma cells 

      Demirović, Aida (Master thesis, 2012)
      Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow. It is the second most common hematological malignancy. The cancer is incurable and the overall survival is 5-7 years. MM can be divided into two equally ...